Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.14% ...

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $154.92 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...

Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline drug, simufilam, failed to meet the primary endpoints in a late study ...

Cassava Sciences’ stock (NASDAQ: SAVA) plummeted on Monday by a staggering 85%. “The results are disappointing for patients ...

Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.

Given Cassava's poor clinical prospects and lack of revenue, I recommend selling SAVA stock and looking for better biotech opportunities. Based on Simufilam's clinical trial history and concerns ...

"Pharma Bro" Martin Shkreli predicted the stock's fall Sunday night. Discover Fast-Growing Stocks Every Month Cassava Sciences SAVA stock is falling Monday after the company shared an update on ...